Tracy Staton

Biography for Tracy Staton

Tracy Staton, Senior Editor

Tracy Staton is the editor of FiercePharma and FiercePharmaMarketing. She has been a freelance writer for eight years, but before that served as editor of the Dallas Business Journal, editor of Texas Business magazine, and a senior editor at American Way, the inflight magazine of American Airlines. She is based in Vermont, and can be reached at or find her on LinkedIn.

Articles by Tracy Staton

AstraZeneca chief bristles at tying exec pay to Pfizer's spurned £55-per-share bid

Hold on a minute, says AstraZeneca CEO Pascal Soriot. Now that the dust has settled on Pfizer's failed bid for the U.K. company, Soriot disputes the wisdom of tying his pay--and that of his fellow executives--to the would-be return on that defunct deal.

GlaxoSmithKline's India unit eyes sales growth after Novartis vax deal

According to a local exec, good times are ahead for Glaxo's vaccines unit in India--and the company's recent pickup of Novartis' non-flu vaccine assets will help it get there.

With new hopes for German pricing, Novo Nordisk decides to roll out Tresiba there

Novo Nordisk has decided to play ball in Germany. The Danish drugmaker now plans to launch its brand-new diabetes drug Tresiba in that country, despite a notorious pricing policy that Novo feared would interfere with its success.

Why does Gilead's Sovaldi cost $84K in the U.S. and $57K in Britain?

The hue and cry over dramatic drug prices keeps getting louder, with trade groups and associations adding their voices. And in a more worrisome development for branded drugmakers, insurers are stepping up their arm-twisting campaigns.

Boehringer to pay $650M to wrap up thousands of Pradaxa lawsuits

Boehringer Ingelheim has agreed to pay $650 million to wrap up thousands of lawsuits claiming Pradaxa, an anticoagulant, caused serious--even fatal--bleeding in some patients. The deal comes just weeks after the FDA completed a safety review of the drug, concluding that it was as safe as the older drug it seeks to replace, warfarin.

Cancer drugs beware: Docs to get monthly paybacks for sticking to preferred meds

Payers have decided that formularies aren't enough, at least for cancer drugs. As the Wall Street Journal reports, insurers are revamping their reimbursement protocols to strip incentives for pricey meds--and introduce new ones for "preferred" treatments.

Bristol-Myers scores 2 more immuno-oncology deals as ASCO approaches

Bristol-Myers Squibb inked a pair of deals to broaden its immuno-oncology efforts: It will partner with Incyte in testing the latter's drug candidate INCB24360 with its own PD-1 drug nivolumab.

As the deal turns: With the Pfizer-AstraZeneca soap opera canceled, time for second-guessing

Pfizer's run at AstraZeneca is officially at an end. No more will-they-or-won't-they speculation, for at least a few months. What we're hearing now is a story of pride, prejudice, poor timing and miscalculation. CEOs and company boards are people, too, after all.

Delaware counts the cost of a Pfizer takeover of AstraZeneca

The state of Delaware is worried that it would lose AstraZeneca's U.S. headquarters--and the thousands of jobs that go with it--should Pfizer succeed in buying the U.K. company.

Here's an idea for AZ's full-of-promises execs: Tie pay to opportunity cost

Richard Buxton, who heads up the U.K. Equities group at Old Mutual Global Investors, proposes AstraZeneca executives put their money where their mouths are. In other words, Buxton says AZ should tie executive compensation to results similar to the Pfizer payout.